NRIX is trading 10.6% up at $21.35 as investors continue to bid up the stock on optimism surrounding its multi-billion-dollar Roche blood cancer collaboration and a wave of bullish analyst ratings and price target hikes.
- This move extends a strong multi-week rally, with shares climbing steadily since mid-June as sentiment shifts toward Nurix’s clinical pipeline.
- The stock is benefiting from broader biotech sector momentum and increased investor confidence in the company's long-term growth prospects.